About
Leadership
Eflornithine
BRAIN TUMORS
Partnering
News
Contact Orbus
PRIVACY POLICY

Orbus Therapeutics

About
Leadership
Eflornithine
BRAIN TUMORS
Partnering
News
Contact Orbus
PRIVACY POLICY
Teresa Long
March 2, 2021

Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study

Teresa Long
March 2, 2021
Read Full Release
Newer PostOrbus Therapeutics Granted European Patent for Method of Use for Eflornithine
Older PostOrbus Therapeutics Receives U.S. Patent for Eflornithine Formulations
Back to Top
About
Leadership
Board of Directors
Eflornithine
Brain Tumors
Partnering
News
Contact Orbus
Privacy Policy

Orbus Therapeutics  |  2479 E. Bayshore Road, Suite 105  |  Palo Alto, CA 94303  |  650-656-9440

Copyright © Orbus Therapeutics, Inc.  ALL RIGHTS RESERVED